{"title": "Clinical trials", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2017-05-29", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "|E.1 Medical condition or disease under investigation\n|\n|E.1.1||Medical condition(s) being investigated ||\n|\n|Health workers with biological risk in their tasks, who have been vaccinated as non-responders to conventional vaccination against Hepatitis B\n|\n|Trabajadores del \u00e1mbito sanitario con riesgo biol\u00f3gico en sus tareas, que hayan sido vacunados como no-respondedores a la vacunaci\u00f3n convencional contra la Hepatitis B\n|\n|E.1.1.1||Medical condition in easily understood language ||\n|\n|Health workers with biological risk in their tasks, who have been vaccinated as non-responders to conventional vaccination against Hepatitis B\n|\n|Trabajadores del \u00e1mbito sanitario con riesgo biol\u00f3gico en sus tareas, que hayan sido vacunados como no-respondedores a la vacunaci\u00f3n convencional contra la Hepatitis B\n|\n|E.1.1.2||Therapeutic area ||Body processes [G] - Immune system processes [G12]\n|\n|MedDRA Classification\n|\n|E.1.3||Condition being studied is a rare disease || No\n|\n|E.2 Objective of the trial\n|\n|E.2.1||Main objective of the trial ||\n|\n|To benefit and equip SACYL staff with an additional protection tool against hepatitis B infection.\n|\nTo evaluate the efficacy of the adjuvanted vaccine in healthy non-responders to conventional hepatitis B vaccine\n|Beneficiar y dotar al personal de SACYL con una herramienta adicional de protecci\u00f3n frente al contagio por hepatitis B.\n|\nEvaluar la eficacia de la vacuna adyuvada en aquellos sujetos sanos no-respondedores a la vacuna convencional antihepatitis B\n|E.2.2||Secondary objectives of the trial ||\n|\n|To benefit and equip SACYL staff with an additional protection tool against hepatitis B infection.\n|\nTo evaluate the efficacy of the adjuvanted vaccine in healthy non-responders to conventional hepatitis B vaccine\n|Beneficiar y dotar al personal de SACYL con una herramienta adicional de protecci\u00f3n frente al contagio por hepatitis B.\n|\nEvaluar la eficacia de la vacuna adyuvada en aquellos sujetos sanos no-respondedores a la vacuna convencional antihepatitis B\n|E.2.3||Trial contains a sub-study || No\n|\n|E.3||Principal inclusion criteria ||\n|\n|Health workers in the Health Area of Salamanca, Zamora, Leon, Valladolid and Palencia\n|\nCriteria defining them as NO responders to the conventional hepatitis B vaccine: anti HBsAb titers <10 mIU / ml following the application of six doses of conventional vaccine at 20 \u03bcg doses (two complete guidelines)\n|Trabajadores del a\u0301mbito sanitario del A\u0301rea de Salud de Salamanca, Zamora, Leon, Valladolid y Palencia\n|\nCriterios que les definen como NO respondedores a la vacuna convencional para hepatitis B: ti\u0301tulos de Ac antiHBs < 10 mUI/ml tras la aplicacio\u0301n de seis dosis de vacuna convencional a dosis de 20 \u03bcg (dos pautas completas)\nSujetos que firmen el consentimiento informado\n|E.4||Principal exclusion criteria||\n|\n|Known allergy to the active substance or any of the other ingredients of the medicinal product (included in section 6 of the product data sheet).\n|\nIf you have ever had an allergic reaction to any vaccine against hepatitis B\nIf you have a serious infection with fever.\nSubjects for whom informed consent is not obtained\nSubjects that have not revoked the consent initially signed.\n|Alergia conocida al principio activo o a cualquiera de los dem\u00e1s componentes del medicamento (incluidos en la secci\u00f3n 6 de la ficha t\u00e9cnica del producto).\n|\nSi ha tenido alguna vez una reacci\u00f3n al\u00e9rgica a cualquier vacuna frente a la hepatitis B\nSi tiene una infecci\u00f3n grave con fiebre.\nSujetos de los cuales no se obtenga el consentimiento informado\nSujetos que no hayan revocado el consentimiento inicialmente firmado.\n|E.5 End points\n|\n|E.5.1||Primary end point(s)||\n|\n|SACYL health workers with biological risk in their tasks who have been classified as non-responders to vaccination against Hepatitis B\n|\n|Trabajadores del \u00e1mbito sanitario del SACYL, con riesgo biol\u00f3gico en sus tareas, que hayan sido clasificados como no-respondedores a la vacunaci\u00f3n contra la Hepatitis B\n|\n|E.5.1.1||Timepoint(s) of evaluation of this end point||\n|\n|Between 40 and 60 days after the last dose given\n|\n|Entre los 40 y dos 60 d\u00edas despu\u00e9s de la ultima dosis administrada\n|\n|E.5.2||Secondary end point(s)||\n|\n|Analyze results of anti-HBs antibody titers to see the immune response to the adjuvanted vaccine.\n|\nTo evaluate safety results and clinical tolerance of the adjuvanted vaccine\n|Analizar resultados de t\u00edtulos de anticuerpos antiHBs para ver la respuesta inmunol\u00f3gica a la vacuna adyuvada.\n|\nEvaluar resultados de seguridad y la tolerancia cl\u00ednica de la vacuna adyuvada\n|E.5.2.1||Timepoint(s) of evaluation of this end point||\n|\n|Al mes de la adminsitracion\n|\nEn el momento de la administraci\u00f3n de la vacuna y durante el mes posterior\n|Al mes de la adminsitracion\n|\nEn el momento de la administraci\u00f3n de la vacuna y durante el mes posterior\n|E.6 and E.7 Scope of the trial\n|\n|E.6||Scope of the trial\n|\n|E.6.1||Diagnosis|| No\n|\n|E.6.2||Prophylaxis|| Yes\n|\n|E.6.3||Therapy|| No\n|\n|E.6.4||Safety|| Yes\n|\n|E.6.5||Efficacy|| Yes\n|\n|E.6.6||Pharmacokinetic|| No\n|\n|E.6.7||Pharmacodynamic|| No\n|\n|E.6.8||Bioequivalence|| No\n|\n|E.6.9||Dose response|| No\n|\n|E.6.10||Pharmacogenetic|| No\n|\n|E.6.11||Pharmacogenomic|| No\n|\n|E.6.12||Pharmacoeconomic|| No\n|\n|E.6.13||Others|| No\n|\n|E.7||Trial type and phase\n|\n|E.7.1||Human pharmacology (Phase I)|| No\n|\n|E.7.1.1||First administration to humans|| No\n|\n|E.7.1.2||Bioequivalence study|| No\n|\n|E.7.1.3||Other|| No\n|\n|E.7.1.3.1||Other trial type description||\n|\n|E.7.2||Therapeutic exploratory (Phase II)|| No\n|\n|E.7.3||Therapeutic confirmatory (Phase III)|| Yes\n|\n|E.7.4||Therapeutic use (Phase IV)|| No\n|\n|E.8 Design of the trial\n|\n|E.8.1||Controlled|| No\n|\n|E.8.1.1||Randomised|| No\n|\n|E.8.1.2||Open|| Yes\n|\n|E.8.1.3||Single blind|| No\n|\n|E.8.1.4||Double blind || No\n|\n|E.8.1.5||Parallel group|| No\n|\n|E.8.1.6||Cross over || No\n|\n|E.8.1.7||Other|| No\n|\n|E.8.2|| Comparator of controlled trial\n|\n|E.8.2.1||Other medicinal product(s)|| No\n|\n|E.8.2.2||Placebo || No\n|\n|E.8.2.3||Other|| No\n|\n|E.8.3||\nThe trial involves single site in the Member State concerned\n|| No\n|\n|E.8.4|| The trial involves multiple sites in the Member State concerned || Yes\n|\n|E.8.4.1||Number of sites anticipated in Member State concerned||5\n|\n|E.8.5||The trial involves multiple Member States|| No\n|\n|E.8.6 Trial involving sites outside the EEA\n|\n|E.8.6.1||Trial being conducted both within and outside the EEA|| No\n|\n|E.8.6.2||Trial being conducted completely outside of the EEA|| No\n|\n|E.8.7||Trial has a data monitoring committee|| No\n|\n|E.8.8||\nDefinition of the end of the trial and justification where it is not the last\nvisit of the last subject undergoing the trial\n||\n|\n|AT THE MONTH OF THE LAST VISIT OF THE LAST RECRUITED SUBJECT\n|\n|AL MES DE LA ULTIMA VISITA DEL ULTIMO SUJETO RECLUTADO\n|\n|E.8.9 Initial estimate of the duration of the trial\n|\n|E.8.9.1||In the Member State concerned years||1\n|\n|E.8.9.1||In the Member State concerned months||\n|\n|E.8.9.1||In the Member State concerned days||\n|", "language": null, "image": null, "pagetype": null, "links": ["/help.html", "/ctr-search/search", "/joiningtrial.html", "/contacts.html", "/about.html", "/about.html", "/whatsNew.html", "/dataquality.html", "/doc/Sponsor_Contact_Information_EUCTR.pdf", "/natauthorities.html", "/links.html", "/index.html", "/about.html", "https://euclinicaltrials.eu/", "https://eudract.ema.europa.eu/docs/guidance/EudraCT%20FAQ_for%20publication.pdf", "/doc/How_to_Search_EU_CTR.pdf#zoom=100,0,0", "javascript:void(0)", "javascript:void(0)", "#", "javascript:$('#expand').click();window.print()", "javascript:void(0)", null, "results", "javascript:window.location.replace('#A')", "javascript:window.location.replace('#B')", "javascript:window.location.replace('#C')", "javascript:window.location.replace('#D')", "javascript:window.location.replace('#D8')", "javascript:window.location.replace('#E')", "javascript:window.location.replace('#F')", "javascript:window.location.replace('#G')", "javascript:window.location.replace('#N')", "javascript:window.location.replace('#P')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", null, "javascript:window.location.replace('#summary')", "https://eudract.ema.europa.eu/contact.html", "/disclaimer.html", "https://euclinicaltrials.eu/", "http://www.ema.europa.eu", "http://www.hma.eu"]}